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Abstract
Close relationships exist between presence of adiponectin (APN) within vascular tissue and
expression of T-cadherin (T-cad) on vascular cells. APN and T-cad are also present in the
circulation but here their relationships are unknown. This study investigates associations
between circulating levels of high molecular weight APN (HMW-APN) and T-cad in a popu-
lation comprising 66 women and 181 men with angiographically proven stable coronary
artery disease (CAD). Plasma HMW-APN and T-cad were measured by ELISA and ana-
lysed for associations with baseline clinical characteristics and with each other. In multivari-
able analysis BMI and HDL were independently associated with HMW-APN in both
genders, while diabetes and extent of coronary stenosis were independently associated
with T-cad in males only. Regression analysis showed no significant association between
HMW-APN and T-cad in the overall study population. However, there was a negative asso-
ciation between HMW-APN and T-cad (P=0.037) in a subgroup of young men (age <60
years, had no diabetes and no or 1-vessel CAD) which persisted after multivariable analysis
with adjustment for all potentially influential variables (P=0.021). In the corresponding sub-
group of women there was a positive association between HMW-APN and T-cad (P=0.013)
which disappeared after adjustment for HDL. After exclusion of the young men, a positive
association (P=0.008) between HMW-APN and T-cad was found for the remaining partici-
pants of the overall population which disappeared after adjustment for HDL and BMI. The
existence of opposing correlations between circulating HMW-APN and T-cad in male and
female patient populations underscores the necessity to consider gender as a confounding
variable when evaluating biomarker potentials of APN and T-cad.
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Introduction
Adiponectin (APN), a 28-30kDa protein abundantly secreted into the circulation by adipocytes,
possesses anti-inflammatory, anti-atherogenic, insulin-sensitizing and cardioprotective proper-
ties (reviewed in [1–4]). Circulating APN exists in different forms (monomeric, oligomeric and
multimeric, high-molecular-weight (HMW)) [1–4], and among them the HMW oligomer is
most abundant and considered physiologically most relevant [1–4]. Plasma concentrations of
APN have been frequently found to be reduced in obesity, metabolic syndrome, type 2 diabetes,
hypertension, coronary artery disease (CAD) and acute coronary syndrome (ACS) [1,2].
T-cadherin (T-cad), a cell surface glycosylphosphatidylinositol (GPI)-anchored cadherin
family member, is a binding protein for hexameric and HMW-APN [5]. In vascular tissue T-
cad and APN display common cellular localization patterns. T-cad is expressed on endothelial
cells (EC) and vascular smooth muscle cells (SMC) with high expression in the subendothelial
SMC layer [6]. APN is present on the luminal surface of human atherosclerotic tissues [7] and
murine aorta [8,9], and also localizes to the subendothelial and medial layers of catheter-
injured rat aortae [10] and human atherosclerotic lesions with damaged endothelium [7]. Stud-
ies using T-cad-deficient mice have demonstrated that T-cad expression on EC is essential
both for binding and localization of APN to vascular tissues [8,9,11] and for mediating amelio-
rative revascularization actions of APN following cardiac ischemia-reperfusion injury and hind
limb ischemia [11,12].
In addition to its cellular localization, T-cad is also present in the circulation as a component
of microparticles (MPs) [13], which are submicron plasma membrane vesicles shed into the
extracellular space from cells undergoing stress, activation or apoptosis [14]. MPs are now
widely considered as both biomarkers and active participants (beneficial and/or detrimental)
for numerous diseases with vascular involvement [14]. In vitro and in vivo studies have shown
that T-cad is shed from stressed/apoptotic EC and in amounts reflecting the extent of EC acti-
vation and damage [13]. Furthermore, and similarly to the vasculoprotective actions of T-cad
expressed on the EC surface, MP-conveyed T-cad induces prosurvival signal transduction and
angiogenic behaviour in target EC [13,15–18]. These actions of T-cad are independent of its
function as a receptor for APN and are mediated via homophilic ligation (T-cad-T-cad) inter-
actions [13,15–18]. Given the importance of EC surface-expressed T-cad for recruitment of
APN to vascular tissues [8,9,11], shedding of T-cad from the surface of EC into the circulation
might possibly also influence circulating levels of APN.
Associations between levels of APN and T-cad in the circulation have never been studied.
However, information regarding biomarker relevance for circulating T-cad does suggest some
analogies with circulating APN, for which hypoadiponectemia is typically found in diabetes,
metabolic syndrome and coronary artery disease [1,2]. Plasma concentrations of T-cad were
found to be decreased in association with increasing severity of coronary artery disease and a
higher risk for ACS [19]. Further, in the overall population (comprising patients with normal
coronary arteries, chronic CAD or ACS) levels of circulating T-cad were lower in males, in
patients with diabetes or hypertension, negatively correlated with body mass index (BMI) and
positively correlated with high density lipoprotein (HDL) [19]. These observations, taken
together with all experimental evidence for common expression patterns for APN and T-cad
within vascular tissue, their direct physical interaction and their involvement in similar patho-
physiological processes led us to hypothesize that there might be some relationships/correla-
tions between the levels of APN and T-cad in the circulation. In order to test this hypothesis
we performed a parallel analysis of HMW-APN and T-cad in plasma from patients with stable
CAD and evaluated their individual associations with baseline clinical characteristics and their
associations with each other.
Associations between Circulating T-Cadherin and Adiponectin
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Patients and Methods
Study population
The subjects include patients who underwent coronary angiography for the evaluation of CAD
at the hospital of Lucerne, Switzerland. The decision to perform coronary angiography was
made by the cardiologist in charge based on non-invasive clinical examinations. We excluded
patients who presented acutely with ST-segment elevation myocardial infarction, non-ST-
segment elevation myocardial infarction or unstable angina, because the acute event can per-
turb APN and T-cad [19,20]. The present study therefore embraced patients with stable condi-
tion. All patients had either CAD (defined as coronary stenosis of 50% or more in at least 1
coronary vessel) or coronary sclerosis (defined as angiographically visible coronary irregulari-
ties of less than 50% lumen narrowing). All patients provided written informed consent. The
institutional ethical committee approved the study (Ethikkommission des Kantons Luzern,
approval no. 536), which was conducted in compliance with the Declaration of Helsinki.
Clinical measurements
In all patients, clinical characteristics (age, gender, cardiovascular risk factors, medical history,
and clinical presentation) were assessed at baseline. Hypertension was defined as increased
blood pressure (BP)140/90 mmHg, or current treatment for hypertension. Dyslipidemia was
defined as total cholesterol>234 mg/dl (6.0 mmol/L) or low-density lipoprotein cholesterol
>117 mg/dl (3.0 mmol/L), or usage of drug therapies for dyslipidemia. Diagnosis of diabetes
mellitus was made if fasting plasma glucose was7 mmol/L on2 different days or if post-
prandial plasma glucose was11.1 mmol/L. Patients were considered smokers if they currently
smoked1 cigarette per week. Patients who previously stopped smoking were considered non-
smokers. A positive family history of CAD was defined as evidence of CAD in a parent or sib-
ling<60 years old. We defined metabolic syndrome as BMI30 kg/m2 and the presence of at
least two of either hypertension, dyslipidemia or diabetes [21].
Measurement of T-cad and HMW-APN in plasma
Blood samples were drawn after overnight fasting from all patients prior to elective angiogra-
phy after a 20–30 min resting period in the supine position. Blood samples drawn into 10-ml
sodium heparin vacutainer tubes (BD Biosciences, Erembodegem, Belgium) were centrifuged
at 3’500xg for 25 min at room temperature. The cell-free plasma samples were aliquoted into
polypropylene tubes, snap-frozen and stored at—70°C until analysis. The concentration of T-
cad in plasma was determined by double sandwich immunoassay on the Meso Scale Discovery
electrochemiluminescence platform (MSD; Rockville, Maryland, USA) following protocols
exactly as detailed previously [19]. Capture antibody was polyclonal mouse anti-T-cadherin
antibody (Sigma-Aldrich Chemie, Buchs, Switzerland) and detection was performed using bio-
tin-conjugated goat polyclonal anti-T-cadherin antibody (R&D Systems Europe Ltd., Abing-
don, UK) and streptavidin Sulfo-TAG (MSD). The concentration of HMW-APN in plasma
was measured by enzyme-linked immunosorbent assay (ELISA) using the Quantikine ELISA
kit for human HMWAdiponectin/Acrp30 (R&D Systems Europe Ltd., Abingdon, UK). The
assays were run according to the manufacturer’s protocol. Concentrations of T-cad and
HMW-APN in plasma samples were measured blinded to the clinical data.
Statistical Analysis
First, we excluded patients from the analysis who had HMW-APN/T-cad-ratio200, based on
the assumption that these patients probably had measurement error of HMW-APN and/or T-
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cad. Second, we imputed missing values for cholesterol measurements in 5 patients using the
median values. Third, we descriptively analyzed baseline findings for the overall study popula-
tion. Baseline characteristics were also analyzed separate for male and female participants
based on our observations during preliminary analyses that there were gender-specific differ-
ences in HMW-APN and T-cad. Fourth, we used linear regression models to search for bivari-
able associations between HMW-APN or T-cad and eighteen baseline findings separate for
male and female participants. We searched for associations with all investigated baseline char-
acteristics, but only report those that showed a significant association. For each regression
model, R2, coefficients and p values are provided. Owing to skewness, HMW-APN was log
transformed for linear regression analysis using the natural logarithm. Fifth, we used a multi-
variable linear regression model to determine independent associations of baseline findings
with HMW-APN or T-cad as dependent variables. As independent variables, we selected all
baseline variables that showed significant associations in bivariable analysis. Sixth, we per-
formed bivariable linear regression analysis to search for associations between log transformed
HMW-APN and T-cad. For significant associations, multivariable models were additionally
performed with adjustment for each of the following variables: age, sex, BMI, blood pressure,
hypertension, dyslipidemia, diabetes, CAD severity, HDL and triglycerides. These analyses
were performed in the overall population, separate for both genders, and according to age
(age< 60 years vs. age 60 years). We used Student's t test to compare continuous variables
with normal distribution and Wilcoxon rank-sum test for variables with non-normal distribu-
tion. For categorical variables, chi-square test or, if cell counts were less than 5, Fisher’s exact
test was used. Data were analyzed using STATA 12.1 (StataCorp, College Station, Texas, USA).
A significance level of 0.05 was assumed for all tests.
Results
Study group characteristics
The study population embraced 250 patients. Three patients (1.2%) with probable measure-
ment error for HMW-APN and/or T-cad were excluded resulting in an analysed population of
247 patients. Table 1 presents the demographic and clinical characteristics of the study group
as a whole and according to gender. Male study participants had higher BMI, lower HDL cho-
lesterol and higher creatinine than female study participants, they more often were on a pre-
scription for ACE inhibitors, ARBs or statins, and they had more severe CAD on angiography.
Table 1 also displays HMW-APN and T-cad values: female study participants had signifi-
cantly higher HMW-APN than male participants (as expected [1–4]), whereas for T-cad only a
statistically non-significant trend towards higher values in females was found.
Associations of HMW-APN and T-cad with baseline characteristics
Table 2 shows bivariable associations of circulating HMW-APN and T-cad with baseline char-
acteristics separate for male and female participants. Plasma levels of HMW-APN correlated
negatively with BMI and positively with HDL in both males and females. As measured by the
R2, these associations were relatively strong. For both genders, negative correlations were
found between HMW-APN and certain cardiovascular risk factors (dyslipidemia in males; sys-
tolic BP and diabetes in females). In addition, HMW-APN positively correlated with age and
negatively with previously known CAD and triglycerides in males. Plasma levels of T-cad cor-
related negatively with BMI, the presence of hypertension and the use of an ACE inhibitor or
ARB in both males and females. Further negative associations were found with diabetes and
the extent of CAD in males, and with systolic BP in females. In female participants, T-cad posi-
tively correlated with HDL.
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Multivariable analyses showed that the negative association of BMI with HMW-APN was
independent from other baseline variables in males (coefficient -0.02 [95% CI -0.04 –-0.00],
P = 0.045) and females (coefficient -0.03 [95% CI -0.06 –-0.00], P = 0.038). Using multivariable
analyses, the positive association of HDL with HMW-APN was independent from other base-
line variables in males (coefficient 0.43 [95% CI 0.16–0.71], P = 0.002) and nearly independent
in females (coefficient 0.23 [95% CI -0.07–0.54], P = 0.129). Other significant bivariable
Table 1. Demographic and clinical characteristics of the study group and according to gender.
Variable All patients (n = 247) Male (n = 181) Female (n = 66) P value
Age (years), mean ± SD 60.7 ± 9.9 60.2 ± 10.0 62.2 ± 9.5 0.174
BMI (kg/m2), mean ± SD 27.4 ± 4.7 27.8 ± 4.5 26.3 ± 4.9 0.011
Systolic BP (mmHg), mean ± SD 131 ± 18 130 ± 18 133 ± 20 0.403
Diastolic BP (mmHg), mean ± SD 75 ± 10 76 ± 10 73 ± 11 0.108
Cardiovascular risk factors
Hypertension, n (%) 161 (65.2) 117 (64.6) 44 (66.7) 0.767
Diabetes, n (%) 42 (17.0) 32 (17.7) 10 (15.2) 0.640
Current smoker, n (%) 52 (21.1) 42 (23.2) 10 (15.2) 0.170
Dyslipidemia, n (%) 180 (72.9) 136 (75.1) 44 (66.7) 0.185
Family history of CAD, n (%) 95 (38.5) 64 (35.4) 31 (47.0) 0.097
Metabolic syndrome, n (%) 44 (17.8) 35 (19.3) 9 (13.6) 0.300
Medication1
ACE inhibitor/ARB, n (%) 108 (43.7) 86 (47.5) 22 (33.3) 0.047
Betablocker, n (%) 137 (55.5) 103 (56.9) 34 (51.5) 0.451
Statin, n (%) 147 (59.5) 114 (63.0) 33 (50.0) 0.066
Medical history and co-morbidities
Previously known CAD, n (%) 54 (21.9) 45 (24.9) 9 (13.6) 0.059
History of ACS, n (%) 13 (5.3) 11 (6.1) 2 (3.0) 0.523
History of stroke, n (%) 11 (4.5) 10 (5.5) 1 (1.5) 0.297
Known PAD, n (%) 18 (7.3) 13 (7.2) 5 (7.6) 0.916
Known COPD, n (%) 10 (4.1) 7 (3.9) 3 (4.6) 0.730
Findings during coronary angiography
Number of coronary arteries with stenosis 50%, n (%)
! 0 55 (22.3) 34 (18.8) 21 (31.8) 0.011
! 1 73 (29.6) 49 (27.1) 24 (36.4)
! 2 60 (24.3) 47 (26.0) 13 (19.7)
! 3 59 (23.9) 51 (28.2) 8 (12.1)
Lipid measurements and creatinine
LDL cholesterol (mmol/L), mean ± SD 2.7 ± 1.1 2.6 ± 1.1 2.9 ± 1.1 0.055
HDL cholesterol (mmol/L), mean ± SD 1.4 ± 0.4 1.3 ± 0.4 1.7 ± 0.4 <0.001
Triglycerides (mmol/L), mean ± SD 1.5 ± 1.1 1.5 ± 1.2 1.3 ± 0.7 0.635
Creatinine (μmol/L), mean ± SD 80 ± 16 83 ± 15 71 ± 14 <0.001
HMW-adiponectin and T-cadherin
HMW-adiponectin (μg/mL), mean ± SD 5.5 ± 3.8 4.6 ± 3.1 7.9 ± 4.4 <0.001
T-cadherin (ng/mL), mean ± SD 143.7 ± 33.2 141.7 ± 32.5 149.2 ± 34.7 0.116
Abbreviations: ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; BP, blood pressure; CAD,
coronary artery disease; COPD, chronic obstructive pulmonary disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery
disease; SD, standard deviation. P values compare female and male study participants.
1 Long-term medication within two weeks before study inclusion.
doi:10.1371/journal.pone.0131140.t001
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associations between baseline variables and HMW-APN were weaker in multivariable analyses.
Regarding T-cad, presence of diabetes (coefficient -14.77 [95% CI -27.12 –-2.43], P = 0.019)
and numbers of coronary vessels with significant stenosis (coefficient -4.35 [95% CI -8.62
–-0.09], P = 0.045) were negatively and independently associated in males, whereas other base-
line findings in males and findings in females showed no association in multivariable analyses.
Associations between levels of HMW-APN and T-cad
In the overall study population, no significant association was found between HMW-APN and
T-cad (R2 0.01, coefficient 0.002 [95% CI -0.001–0.004], P = 0.144). However, we observed a
significant negative association in a subgroup of 42 younger men (age< 60 years) who were
relatively healthy (had no diabetes and no or 1-vessel CAD) (R2 0.10, coefficient -0.008 [95%
CI -0.015 –-0.001], P = 0.037) (Fig 1A). The significant association persisted in the multivari-
able model (P = 0.021). In contrast, in the corresponding subgroup of 20 young and healthy
women a relatively strong positive association was found (R2 0.30, coefficient 0.008 [95% CI
0.002–0.013], P = 0.013) (Fig 1B). In this group, the significant association persisted for all
adjustment variables with the exception of HDL, where there was no longer an association
between HMW-APN and T-cad (P = 0.592). After exclusion of the 42 young and healthy men,
a significant positive association between HMW-APN and T-cad was found for the 205
remaining participants of the overall population (R2 0.03, coefficient 0.004 [95% CI 0.001–
0.006], P = 0.008) (Fig 1C). This significant association disappeared after adjustment for BMI
(P = 0.117) and HDL (P = 0.131).
Discussion
This prospective cohort study of patients with chronic stable CAD is the first to investigate
associations between circulating HMW-APN and circulating T-cad. The most significant find-
ing of our study is that associations between HMW-APN and T-cad were gender-specific in
patients< 60 years, being positive in females but negative in males. Multivariable regression
analysis with adjustment for age, sex, BMI, BP, hypertension, dyslipidemia, diabetes, CAD
severity, HDL and triglycerides revealed that HDL is the relevant contributor to the positive
Table 2. Bivariable associations between circulating HMW-adiponectin or T-cadherin and baseline characteristics according to gender.
Characteristic HMW-adiponectin T-cadherin
Male Female Male Female
R2 Coeff P value R2 Coeff P value R2 Coeff P value R2 Coeff P value
Age 0.04 0.01 0.009 0.02 0.01 0.206 0.01 -0.31 0.199 0.01 -0.27 0.556
BMI 0.08 -0.04 <0.001 0.19 -0.05 <0.001 0.03 -1.24 0.020 0.06 -1.75 0.046
Systolic BP 0.00 0.00 0.459 0.14 -0.01 0.002 0.02 -0.25 0.066 0.09 -0.53 0.016
Hypertension 0.00 -0.06 0.531 0.04 -0.25 0.101 0.05 -14.9 0.003 0.06 -18.3 0.042
Diabetes 0.00 0.03 0.815 0.13 -0.57 0.003 0.06 -20.2 0.001 0.00 -4.6 0.705
Dyslipidemia 0.04 -0.31 0.005 0.00 -0.03 0.858 0.00 3.52 0.530 0.00 -2.43 0.791
ACE inhibitor/ARB 0.00 0.06 0.557 0.03 -0.21 0.158 0.03 -11.5 0.017 0.06 -18.2 0.044
Number of coronary arteries with stenosis 50% 0.01 -0.04 0.327 0.00 0.01 0.872 0.03 -5.38 0.016 0.01 -2.95 0.498
HDL cholesterol 0.14 0.66 <0.001 0.14 0.48 0.002 0.00 2.21 0.737 0.07 21.2 0.027
Triglycerides 0.07 -0.15 <0.001 0.03 -0.14 0.152 0.00 -1.74 0.408 0.04 -9.48 0.107
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CAD, coronary artery
disease; CI, conﬁdence interval; HDL, high-density lipoprotein.
doi:10.1371/journal.pone.0131140.t002
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Fig 1. Regression plots showing relationships between HMW-APN and T-cad. Associations between
HMW-APN and T-cad in the subgroups of young (age < 60, had no diabetes and no or 1-vessel CAD) males
(A) or females (B) and in the overall population minus the young male subgroup (C) were determined by
bivariable linear regression analyses. Data are presented as fitted regression plots (solid lines) with 95%
confidence intervals (dashed lines) for the fits and significance levels (P).
doi:10.1371/journal.pone.0131140.g001
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association between HMW-APN and T-cad in females, while the negative association in males
was independent of all the adjusted variables.
We have reported higher levels of circulating T-cad in females vs. males in a cohort embrac-
ing patients with normal coronary arteries, stable CAD and ACS [19], whereas in the present
study on only patients with stable CAD plasma T-cad was not significantly different between
males and females. The gender dimorphism of our previous study may therefore reflect that T-
cad levels were lowest in the ACS patient group and that this group consisted predominantly
(80%) of males [19]. The present study shows that gender issues are important only for T-cad
per se but also for associations between T-cad and HMW-APN.
The gender-related association between T-cad and HMW-APNmay relate to hormonal
control. Both proteins can be regulated by androgens and estrogens. APN secretion by adipo-
cytes is suppressed by testosterone [22,23] and estrogen [24]. Data on the correlations of circu-
lating APN with hormonal status in women are conflicting. Some investigators have shown
that transition to menopause is accompanied with increased circulating APN [25], which is
consistent with the data on estrogen-dependent suppression of APN [24]. Others, however,
have reported lack of correlations between age and APN in females [22,26] or between serum
APN and estradiol levels [27,28], very small [25] or no [27] differences in APN between pre-
and post-menopausal women, and very small [28] or no [27] effects of estrogen replacement
therapy on APN in post-menopausal females. With respect to T-cad, its expression was upre-
gulated in castrated mice and downregulated following androgen replacement [29], while estra-
diol and progesterone were reported to upregulate T-cad expression in osteosarcoma cells in
vitro [30]. We did not measure serum levels of sex hormones and therefore cannot asses causa-
tive contribution to the gender-specific associations between HMW-APN and T-cad reported
herein. Nevertheless, our finding from multivariable analysis that the positive association in
younger females depended on HDL may support our suggestion of some hormonal influence
on the relationship between T-cad and HMW-APN-APN relationship since women have
higher HDL levels due to actions of estrogen [31,32].
Regulation of APN and T-cad by hormones or other effectors is further complicated by the
fact that the two proteins reciprocally influence their expression levels. T-cad-deficient mice
exhibited elevated levels of circulating HMW-APN [11,12] and genome-wide association stud-
ies have linked variants in T-cad gene to elevated [33] or decreased [34] circulating levels of
APN in humans, supporting that circulating APN is influenced by the presence and/or func-
tionality of T-cad. Conversely, APN-deficient mice exhibited a reduced tissue level of T-cad
protein that was restorable in vivo by delivery of exogenous APN [11,12]. Administration of
APN to cardiomyocytes injured by hypoxia/reoxygenation in vitro also upregulated T-cad pro-
tein expression [35], and in a model of liver fibrosis elevated circulating APN was associated
with elevated hepatic expression of T-cad [36]. Thus, tissue T-cad can negatively regulate circu-
lating APN levels by promoting its clearance from blood and sequestration to tissues (“negative
T-cad-to-APN regulation”) [9,11,12], while APN can positively regulate tissue T-cad expres-
sion (“positive APN-to-T-cad feedback regulatory loop”) [9,11]. Such bidirectional regulation
may permit us to formulate a working hypothesis that attempts to explain the observed gen-
der-dependent associations between circulating APN and T-cad. In young men who have rela-
tively low serum APN levels (vs. older men and especially women) T-cad efficiently sequesters
APN from blood (i.e. “negative T-cad-to-APN regulation” is active); however a low level of
APN may not be sufficient to induce the “positive APN-to-T-cad feedback regulatory loop”, so
the resulting association between two proteins in plasma is negative. On the other hand in
women higher serum APN levels result in less efficient APN clearance by T-cad and APN-
dependent upregulation of T-cad expression is initiated in order to meet increased needs for
APN clearance; in this circumstance the “positive APN-to-T-cad feedback regulatory loop”
Associations between Circulating T-Cadherin and Adiponectin
PLOS ONE | DOI:10.1371/journal.pone.0131140 June 17, 2015 8 / 12
overrides “negative T-cad-to-APN regulation”, and the resulting correlation between the pro-
tein levels in plasma is positive. In an overall population the opposing gender-associated corre-
lations "neutralize" each other or co-exist in a bidirectional, intermediate state of equilibrium,
so the resulting analysis shows no correlation between APN and T-cad.
Whatever the mechanisms involved, dynamic modulation of APN and/or T-cad levels may
have important implications for the course of cardiovascular disease since both molecules exert
anti-atherogenic and revascularization actions. In EC APN exerts a number of vasculoprotec-
tive actions that include suppression of adhesion molecules, superoxide generation and apo-
ptosis, and the promotion of angiogenesis/revascularization [2,11,37,38]. Importantly, and
although APN-induced signaling in EC is mediated via AdipoR1 and AdipoR2, this signalling
crucially depends upon the presence of T-cad on EC [11,12,38]. T-cad has thus been attributed
functions as a co-receptor that localizes APN to the endothelium for presentation to signal
transduction-competent AdipoR1 or AdipoR2 [39]. Independently of this co-receptor func-
tion, T-cad per se expressed either on the surface of EC or as a component of circulating EC-
derived microparticles promotes prosurvival and proangiogenic behaviour in EC [13,15–18].
Reduced tissue (and thereby circulating) T-cad will both diminish its reparative and protective
functions in the vasculature [19] and impair binding of APN molecules to the endothelium
with a concomitant reduction of APN-driven vasculoprotective signals [11,12]. Further studies
aimed at analysis of changes in circulating APN and T-cad levels in parallel with histochemical
analyses of the presence, expression level and localization pattern of their cell-bound pools in
the vascular wall at different stages of cardiovascular disease will help to better understand the
impact of dynamic interactions between the two proteins on the progression on cardiovascular
disorders.
It needs to be recognized that changes in circulating T-cad may not exclusively reflect the
state of endothelial integrity and/or dysfunction and that the concentration of circulating APN
does not solely reflect the balance of sequestration to, and release from, the endothelium. T-cad
was first detected (by FACS analysis) in human plasma as a component of EC-derived micro-
particles [13] and thus its concentration in the circulation was presumed to reflect a combina-
tion of the burden of protein expressed on the surface of EC, extent of endothelial activation
and MP shedding and degree of endothelial erosion [19]. However, since plasma levels of T-
cad were analysed by ELISA we cannot exclude contributions from other sources or forms (e.g.
cleaved or secreted) of T-cad. SMC abundantly express T-cad and can also shed MPs [40]. T-
cad is also expressed in adipose tissue [41] and was very recently identified (by ESI-LC-MS/MS
proteomic profiling) as a novel component of the secretome of adipocytes isolated from murine
visceral adipose tissue [42]. Moreover, levels of T-cad were much less abundant in the secre-
tome from diabetes-susceptible mice [42], which is concordant with the previous finding of
lower levels of T-cad in diabetic patients as compared to patients without diabetes [19]. Circu-
lating APN is predominantly derived from adipocytes but several other cell types including car-
diomyocytes [43], SMC [44] and EC [8,45] can also synthesize and secrete APN. T-cad is
expressed on the surface of these cell types [46–48] and therefore locally produced APN
together with circulating adipocyte-derived APN may have important autocrine mechanisms
of action.
Study limitations
First, the study was performed at a single center which may preclude generalizability. Second,
the study is limited by reliance on data obtained from a single blood collection from each
patient. Third, we measured only HMW-APN and not total APN. However very close correla-
tions between total APN and HMW-APN (r2 = 0.969, P< 0.0001 [49] and r2 = 0.786,
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P< 0.0001 [50]) together with effective biomarker usefulness of HMW-APN (vs. total APN or
HMW-total ratio) [49–51] have been demonstrated, and in the context of cardiovascular pro-
tective actions HMW-APN is regarded as the active form of this adipokine [49,51,52]. Addi-
tionally, in the context of associations between T-cad and APN a number of genome-wide
studies revealed that association of SNPs in CDH13 gene were much stronger with levels of
HMW-APN as compared total APN levels [33,53]. Fourth, and with regard to gender-issues,
levels of testosterone and estradiol were not measured.
Conclusions
This study in patients with stable CAD demonstrates the existence of gender-specific associa-
tions for circulating HMW-APN and T-cad with baseline clinical characteristics and important
opposing correlations between circulating APN and T-cad in male and female patients
aged< 60 years. The findings are indicative of a complexity of mechanisms underlying the
APN and/or T-cad regulated axis of cardiovascular disease and underscore the necessity to con-
sider gender as a confounding variable when evaluating biomarker potentials of APN and T-
cad. Larger prospective studies in populations across the cardiovascular disease spectrum are
warranted, in particular studies that elucidate the causal relationship between these biomarkers.
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